Dr. Eboni Green
June 18, 2026
When a loved one runs out of standard treatment options, knowing what to ask about next can make a meaningful difference. Family caregivers may be able to help explore emerging treatments that ease symptoms, improve quality of life, or offer access to promising therapies still in development. While many of these options remain in the trial stage, understanding how they work can help you have better-informed conversations with doctors, specialists, and care teams. From clinical trials and compassionate use to off-label medication and named-patient programs, several pathways may be worth discussing depending on the condition, timing, and available medical evidence.
As a caregiver, you have a firsthand understanding of your loved one’s needs, which can make you a strong advocate when researching clinical trials that may help. Through systems such as community-based clinical research sites, caregivers can act on behalf of patients to match medical history with upcoming trials. These trials are not always a guarantee, but they can help test the effectiveness of new medications and treatments. They may also provide access to specialists, monitoring, and therapies that would otherwise be unavailable. Before pursuing a trial, it is important to review eligibility criteria, possible side effects, travel requirements, and whether the study involves a placebo group.
If your loved one has a serious and life-threatening condition, there could be hope in the form of compassionate use of medical products. This is one of the rarest methods of treatment and is only for granted if there are no other viable alternatives and access to investigational products might help. This can only be accessed through a doctor’s request, where they contact the pharma company with the treatment and secure legal permissions from the governing medical body. Because approval is handled case by case, the process may take time and require substantial medical documentation. Caregivers can help by organizing records, tracking previous treatments, and supporting communication between providers and manufacturers.
Early access programs can be highly effective for certain conditions. For example, the UK’s Early Access to Medicines Scheme (EAMS) has helped more than 1,200 people with conditions such as cancer and Duchenne Muscular Dystrophy. There are also many other examples of technologies that help improve the delivery of care through systems such as pre-approval. In addition, drug companies may offer programs for testing unlicensed or still-unapproved medicines. These options are especially relevant when promising treatments are close to approval but not yet widely available. For caregivers, it can be helpful to ask physicians whether a patient qualifies and what oversight, follow-up appointments, or financial considerations may be involved.
Medications are rarely used to treat only one condition, and doctors regularly prescribe what is intended for one medical issue to address another. This is known as off-label medication. A common example is sildenafil, which was originally developed to relieve high blood pressure but is now commonly prescribed for erectile dysfunction. You can discuss off-label medication with doctors if already-prescribed treatment is not working, but its use is ultimately at the doctor’s discretion. In some situations, off-label prescribing may offer a practical alternative when standard treatment has failed or caused unwanted side effects. Even so, caregivers should ask about the evidence supporting that use, possible interactions, and how effectiveness will be monitored.
Clinical trials and medication approvals can take years, or even decades, to gain approval from agencies such as the US’s FDA. However, there may be medications that could genuinely help but are still awaiting approval in your country. With named-patient programs, doctors can request permission to import drugs approved in other countries that have shown benefit for a specific condition, provided they also secure approval from the relevant medical authority. This route may be especially important for rare diseases or urgent cases in which approved domestic options are limited. As a caregiver, you can support the process by helping gather medical records, understanding import requirements, and staying informed about timelines and costs.
Taking part in clinical trials helps when accessing emerging treatment for loved ones who need alternatives to prescribed medication. You can also sign up to early access programs like the UK’s EAMS, and doctors can access unapproved drugs through named-patient programs. For family caregivers, the key is understanding which option may fit the patient’s condition, medical history, and treatment goals. Speaking openly with healthcare providers can help you evaluate risks, timelines, and realistic outcomes while making the strongest possible case for access to promising therapies.
What are emerging treatments? Emerging treatments are therapies that are still being studied, newly approved, or available only through special pathways such as clinical trials, compassionate use, or early access programs.
Can caregivers enroll a loved one in a clinical trial? Caregivers can help research trial options, organize records, and support enrollment discussions, but eligibility and enrollment decisions are made by medical professionals and study teams.
What should caregivers ask a doctor about emerging treatments? Ask whether the patient may qualify for a trial or access program, what risks and side effects are known, how long approval may take, and what costs, travel, or follow-up care may be involved.
